Company intelligence / Profile preview

Eternity Bioscience Inc.

Cranbury, New Jersey, United Statessites.google.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 1

Overview

The company has multiple programs in development, with their BTK inhibitor program reaching Phase 2 clinical trials. Their EZH2 inhibitor program has reached NDA/BLA stage. Several other programs are in preclinical development.

Therapeutic areas: OncologyDermatologyMetabolic DisordersCardiovascular
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

SHR1032

Preclinical

Partnerships

TGTX (licensed two BTK inhibitors for a total value of $347 million)

Beyond the preview

Go deeper on Eternity Bioscience Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eternity Bioscience Inc..

Explore the full profile